Beijing Biostar Pharmaceuticals Updates Board Structure and Committee Leadership

Bulletin Express
Jun 26

Beijing Biostar Pharmaceuticals Co., Ltd. announced a revised list of directors and committee assignments, effective 26 June 2026.

Board leadership • Dr. Tang Li assumes the dual role of Board Chairperson while continuing as Chief Scientific Officer and Chief Marketing Officer. • Dr. Qiu Rongguo serves as Vice-chairperson, Chief Executive Officer and General Manager. • Executive directorship is further supported by Mr. Zhang Cheng and Dr. Guan Jin, both Deputy General Managers. • Non-executive directors are Mr. Tang Jin and Ms. Dai Xuefen. • Independent non-executive directors (INEDs) include Mr. Manfred Shiu Shu Ming, Dr. Ye Chengang and Dr. Zhu Xiaodong.

Committee composition • Audit Committee: chaired by INED Mr. Manfred Shiu Shu Ming; members include Dr. Qiu Rongguo and Mr. Tang Jin. • Nomination Committee: chaired by INED Dr. Ye Chengang; members comprise Dr. Tang Li and Ms. Dai Xuefen. • Remuneration and Appraisal Committee: chaired by INED Dr. Zhu Xiaodong; committee members are Mr. Manfred Shiu Shu Ming and Dr. Ye Chengang. • Strategy Committee: chaired by Dr. Tang Li with Dr. Qiu Rongguo and Dr. Zhu Xiaodong as members.

The updated structure highlights a balanced mix of executive, non-executive and independent directors, with INEDs holding key oversight roles across the Audit, Nomination, and Remuneration committees.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10